Methods of using adipose derived stem cells to treat acute tubular necrosis
AssigneeCytori Therapeutics, Inc.
InventorsJohn K. Fraser, Marc H. Hedrick, Eric Daniels
Life of this patent
Estimating the term…
Abstract
Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.
Claims44
A method for treating acute tubular necrosis (ATN) in a patient, comprising:
- identifying a patient with ATN;
- and
- providing to the patient's renal vasculature an amount of a concentrated population of cells comprising adipose-derived stem cells sufficient to restore blood flow to an ischemic region of the kidney of said patient.
A method for treating acute tubular necrosis (ATN) in a patient, comprising:
- identifying a patient with ATN;
- and
- providing to the patient's renal parenchyma an amount of a concentrated population of cells comprising adipose-derived stem cells sufficient to restore blood flow to an ischemic region of the kidney of said patient.
A method for treating acute tubular necrosis (ATN) in a patient, comprising:
- identifying a patient with ATN;
- and
- contacting the patient's kidney with an amount of a concentrated population of cells comprising adipose-derived stem cells sufficient to restore blood flow to an ischemic region of the kidney of said patient.
A method for treating acute tubular necrosis (ATN) in a patient, comprising:
- identifying a patient with ATN;
- and
- contacting the patient's kidney with an amount of a concentrated population of cells comprising adipose-derived stem cells that is sufficient to increase blood flow to an ischemic region of the kidney said patient, wherein said concentrated population of cells is obtained in a self-contained adipose-derived stem cell processing unit, comprising:
- a tissue collecting container configured to receive and disaggregate adipose tissue, wherein said tissue collecting container is coupled to a cell collection container wherein said coupling defines a closed system in which disaggregated adipose tissue directed from tissue collecting container to cell collection container is not exposed to the external environment;
- and wherein said cell collection container, further comprises a centrifuge that facilitates separation of the cells in a suspension;
- and
- an outlet that is structured to permit concentrated stem cells to be aseptically removed from said self-contained adipose-derived stem cell processing unit.
Dependencies are inferred from the claim text.